IDH2 and astrocytoma (excluding glioblastoma): The latest WHO 2021 classification integrates the combination of histological and molecular grading by incorporating additional genetic data such as TERT promoter mutation, EGFR amplification, and/or copy number changes (7 gain/10 loss) in IDH1/2-wt astrocytomas, as outlined in the cIMPACT-NOW criteria, to define IDH-wt glioblastoma [1].